Rotavirus shedding following administration of RV3-BB human neonatal rotavirus vaccine
The RV3-BB human neonatal rotavirus vaccine aims to provide protection from severe rotavirus disease from birth. A phase IIa safety and immunogenicity trial was undertaken in Dunedin, New Zealand between January 2012 and April 2014. Healthy, full-term (≥ 36 weeks gestation) babies, who were 0–5 d ol...
Main Authors: | Daniel Cowley, Karen Boniface, Nada Bogdanovic-Sakran, Carl D. Kirkwood, Julie E. Bines |
---|---|
格式: | Article |
語言: | English |
出版: |
Taylor & Francis Group
2017-08-01
|
叢編: | Human Vaccines & Immunotherapeutics |
主題: | |
在線閱讀: | http://dx.doi.org/10.1080/21645515.2017.1323591 |
相似書籍
-
Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine
由: Daniel Cowley, et al.
出版: (2018-08-01) -
Rotavirus specific maternal antibodies and immune response to RV3-BB neonatal rotavirus vaccine in New Zealand
由: Mee-Yew Chen, et al.
出版: (2017-05-01) -
Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi
由: Benjamin Morgan, et al.
出版: (2024-09-01) -
Model-based estimation of the impact on rotavirus disease of RV3-BB vaccine administered in a neonatal or infant schedule
由: Nicholas Geard, et al.
出版: (2022-11-01) -
Investigation of rotavirus and coronavirus in neonatal diarrheic calves
由: Mehmet ÇABALAR, et al.